Alinea Pharmaceuticals

About Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. operated as a biopharmaceutical company with a clear focus on developing new treatments for diabetes and associated metabolic disorders. Founded in August 2005 and based in Cambridge, Massachusetts, the company launched with a significant $45 million Series A financing round. This initial funding was led by MPM Capital, with notable participation from SV Life Sciences, Burrill & Co., and Flagship Ventures. At its inception, Robert Mashal, MD, was appointed as President and CEO.

The company's core strategy revolved around a unique operational and financing structure. Instead of building its own discovery infrastructure, Alinea established a multi-year research and development collaboration with the Institute for Diabetes Discovery (IDD). Through this partnership, Alinea gained access to IDD's portfolio, including a compound in Phase II trials, lidorestat, aimed at preventing diabetic complications, and a preclinical program targeting protein tyrosine phosphatase 1b (PTP1b). Alinea was responsible for IND enabling studies, clinical development, and the eventual commercialization of these assets. This model was designed to provide financial flexibility and a focus on late-stage development.

The business was geared towards addressing the large market of metabolic diseases by building a product portfolio through its collaboration with IDD and by in-licensing other complementary programs. The company's operations have since ceased, and it is considered a deadpooled entity. Information from BioPharmGuy suggests it may have become a subsidiary of NKT Therapeutics.